Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial

LESSONS LEARNED. Evidence has suggested that capecitabine‐cisplatin is similar or possibly superior to S‐1‐cisplatin in terms of safety and efficacy for Japanese patients with advanced gastric cancer (AGC). As far as we are aware, our study is the first randomized trial of two regimens consisting of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakami, Hisato, Takeno, Atsushi, Endo, Shunji, Makari, Yoichi, Kawada, Junji, Taniguchi, Hirokazu, Tamura, Shigeyuki, Sugimoto, Naotoshi, Kimura, Yutaka, Tamura, Takao, Fujitani, Kazumasa, Sakai, Daisuke, Shimokawa, Toshio, Kurokawa, Yukinori, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292554/
https://www.ncbi.nlm.nih.gov/pubmed/30115736
http://dx.doi.org/10.1634/theoncologist.2018-0175

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292554/
https://www.ncbi.nlm.nih.gov/pubmed/30115736
http://dx.doi.org/10.1634/theoncologist.2018-0175

Ejemplares similares